Dry Powder Formulation of Treprostinil Appears Safe, Tolerable in PAH
Use of the dry powder formulation of treprostinil, known as LIQ861, has demonstrated safety and tolerability in patients with pulmonary arterial hypertension beyond 2 weeks.
Sheila Jacobs
Contributing Writer https://www.thecardiologyadvisor.com
Sheila Jacobs is the president of STJ Editorial Services. For more than 25 years, Sheila has been providing writing, fact-checking, and editorial services to numerous clients in the medical education, promotional, and managed care arenas, from the conceptual stage through completion of the final editorial product. Her focus has been in a diverse array of therapeutic areas.
